We are currently working on four drugs. All are therapeutic antibodies. The main areas of Mabion interest are therapeutic cancer and autoimmune diseases.
The first monoclonal antibody developed a drug working name MabionCD20 used to treat blood cancer, lymphomas and leukemias, as well as in the treatment of rheumatoid arthritis. The medicine successfully passed the development phase of the manufacturing process and in vitro characterization. Obecie drug enters a phase of clinical trials.
The second drop-down drug antibody is a working name MabionHER2 therapy for breast cancer. The drug is in the development stage of the manufacturing process and analytical methods.
The clinical development of two other antibodies, anti-VEGF and anti-EGFR, is planned for the years 2016-2017.
The fifth project under MABION is to provide stability of the cell line to be targeted introduction of the recombinant protein cDNA into the host genome, enabling stable and efficient overexpression of the protein.
MABION has contracted the development of other recombinant proteins, including human insulin, human insulin analogues, and animal insulins. It is possible to obtain development of the technology analytical methods, as well as a preparation of GMP.